A controlled study of vigabatrin and visual abnormalities
about
Retinal nerve fibre layer characteristics with vigabatrin-associated visual field loss--could scanning laser polarimetry aid diagnosis?Neurotoxic effects of GABA-transaminase inhibitors in the treatment of epilepsy: ocular perfusion and visual performance.Does the Swedish Interactive Threshold Algorithm (SITA) accurately map visual field loss attributed to vigabatrin?Epilepsy patients treated with vigabatrin exhibit reduced ocular blood flow.Drugs and the retina.Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder.Ocular complications of neurological therapy.Tuberous sclerosis complex: neurological, renal and pulmonary manifestationsVigabatrin and visual field defects in pediatric epilepsy patients.Treatment of refractory complex partial seizures: role of vigabatrin.Understanding and interpreting vision safety issues with vigabatrin therapy.Balancing clinical benefits of vigabatrin with its associated risk of vision loss.Postmarketing withdrawal of human medicinal products because of adverse reactions in animals: a systematic review and analysis.Rapid development of visual field defects associated with vigabatrin therapy.Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal.Vigabatrin-associated visual field constriction in a longitudinal series. Reversibility suggested after drug withdrawal.Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose.Modelling the topography of absolute defects in patients exposed to the anti-epileptic drug vigabatrin and in normal subjects using automated static suprathreshold perimetry of the entire 80° visual field.Retinal nerve fiber layer thickness in vigabatrin-exposed patients.Color vision and macular recovery time in epileptic adolescents treated with valproate and carbamazepine.
P2860
Q33280769-D4974752-E01C-4FB8-86EE-C4AACFA4A46CQ34928181-34604F57-9C29-45E4-B844-270E6A7A9A11Q35336784-98FD70B0-4192-488D-AE64-E87F58B4FF37Q35590459-DA0379BA-7A0D-42DC-8AB8-B405E96F7637Q35779346-5B4502B2-0CE5-4932-A806-914CFE7A4620Q36156471-14B45A06-9734-4A8A-A251-3201A2FCCD21Q36164098-E677EA95-9854-460F-9CA3-E5BF162F7BCAQ36239644-D777F74A-C0FD-45B9-81AE-AFEB25D05651Q37313207-81392374-8790-47D1-80CD-2AEAA8D2CFB9Q37620193-DAD39FE4-225F-49C6-830C-5442CFA4934CQ37953582-B7A6C373-A5D3-4363-BB68-384B23EB80CDQ37953583-6A4BDCD1-7361-46E3-B22D-CFD186B3F39EQ38660493-BC997E3A-6202-4EDF-88E9-88D2E1E53CB8Q43795358-2B8C2E33-CD5C-468F-82BE-0421651CC803Q44113272-D8DB06E7-9E53-47A8-9F86-5C8B711998FEQ44358411-914CFF0E-0D0C-45A8-857A-C11AED5BF9FFQ44906627-ACBB2F26-4504-4173-8D30-71BABB0DEE8AQ46793492-8FBEC93E-788D-4805-8A85-F2D8D5F40BB3Q51611825-6FA37E0A-CFFD-4DFF-BCA2-202EFE15BD30Q51796167-8B1C43E3-98C4-435A-9276-1DA727CF5B11
P2860
A controlled study of vigabatrin and visual abnormalities
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
A controlled study of vigabatrin and visual abnormalities
@ast
A controlled study of vigabatrin and visual abnormalities
@en
A controlled study of vigabatrin and visual abnormalities
@nl
type
label
A controlled study of vigabatrin and visual abnormalities
@ast
A controlled study of vigabatrin and visual abnormalities
@en
A controlled study of vigabatrin and visual abnormalities
@nl
prefLabel
A controlled study of vigabatrin and visual abnormalities
@ast
A controlled study of vigabatrin and visual abnormalities
@en
A controlled study of vigabatrin and visual abnormalities
@nl
P2093
P2860
P356
P1476
A controlled study of vigabatrin and visual abnormalities
@en
P2093
K Manuchehri
S Nightingale
P2860
P304
P356
10.1136/BJO.84.5.499
P407
P577
2000-05-01T00:00:00Z